>
Combigene AB logo

COMBI - Combigene AB Share Price

SEK0.42 -0.0  -3.2%

Last Trade - 16/04/21

Sector
Healthcare
Size
Micro Cap
Market Cap £14.3m
Enterprise Value £11.2m
Revenue £n/a
Position in Universe 1484th / 1831
Bullish
Bearish
Unlock COMBI Revenue
Momentum
Relative Strength (%)
1m -11.9%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -70.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 3.00 0.008 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020,Combigene AB revenues was not reported. Net loss applicableto common stockholders increased 67% to SEK29.4M. Highernet loss reflects Other External Expenses increase of 17%to SEK29.6M (expense), Other Operating Income decrease of24% to SEK12M (income), Amortization of Intangiblesincrease from SEK1.2M to SEK2.5M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

COMBI Revenue Unlock COMBI Revenue

Net Income

COMBI Net Income Unlock COMBI Revenue

Normalised EPS

COMBI Normalised EPS Unlock COMBI Revenue

PE Ratio Range

COMBI PE Ratio Range Unlock COMBI Revenue

Dividend Yield Range

COMBI Dividend Yield Range Unlock COMBI Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
COMBI EPS Forecasts Unlock COMBI Revenue
Profile Summary

Combigene AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in development of treatments for neurological disorders. The Company's platform comprises the use of gene therapy vectors delivering a combination of transgenes encoding two or more of neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors, for the treatment of neurological and psychiatric diseases in humans and animals. The Company focuses on the development of an epilepsy treatment by means of an adeno-associated virus (AAV) vector carrying the transgenes for the neurotransmitter NPY and one of its receptors, the G protein-coupled receptor Y2.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Public Since May 25, 2015
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange OMX Nordic Exchange Stockholm
Shares in Issue 396,023,950
Free Float (0.0%)
Eligible for
ISAs
SIPPs
COMBI Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for COMBI
Upcoming Events for COMBI
Frequently Asked Questions for Combigene AB
What is the Combigene AB share price?

As of 16/04/21, shares in Combigene AB are trading at SEK0.42, giving the company a market capitalisation of £14.3m. This share price information is delayed by 15 minutes.

How has the Combigene AB share price performed this year?

Shares in Combigene AB are currently trading at SEK0.42 and the price has moved by -17.58% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Combigene AB price has moved by -36.13% over the past year.

What are the analyst and broker recommendations for Combigene AB?

Of the analysts with advisory recommendations for Combigene AB, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Combigene AB is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Combigene AB next release its financial results?

Combigene AB is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Combigene AB dividend yield?

Combigene AB does not currently pay a dividend.

Does Combigene AB pay a dividend?

Combigene AB does not currently pay a dividend.

When does Combigene AB next pay dividends?

Combigene AB does not currently pay a dividend.

How do I buy Combigene AB shares?

To buy shares in Combigene AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Combigene AB?

Shares in Combigene AB are currently trading at SEK0.42, giving the company a market capitalisation of £14.3m.

Where are Combigene AB shares listed? Where are Combigene AB shares listed?

Here are the trading details for Combigene AB:

Country of listing: Sweden
Exchange: STO
Ticker Symbol: COMBI
What kind of share is Combigene AB?

Based on an overall assessment of its quality, value and momentum, Combigene AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Combigene AB share price forecast 2021?

Shares in Combigene AB are currently priced at SEK0.42. At that level they are trading at 0.448% discount to the analyst consensus target price of 0.00.

How can I tell whether the Combigene AB share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Combigene AB. Over the past six months, the relative strength of its shares against the market has been -54.48%. At the current price of SEK0.42, shares in Combigene AB are trading at -41.35% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Combigene AB PE Ratio?

We were not able to find PE ratio data for Combigene AB.

Who are the key directors of Combigene AB?

Combigene AB's management team is headed by:

Jan Nilsson - CEO
Karin Agerman - VRD
Arne Ferstad - CHM
Hilde Furberg - DRC
Susana Ayesa Alvarez - DRC
Peter Nilsson - DRC
Lars Thunberg - DRC
Louise Aspenberg - CFO
Who are the major shareholders of Combigene AB?

Here are the top five shareholders of Combigene AB based on the size of their shareholding:

Similar to COMBI
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.